Biogen Competitive Strategy & Market Position
Biogen's edge is more than four decades of neurology experience: relationships with neurologists and MS and SMA treatment centers, experience running long central nervous system trials, antisense know-how built with Ionis (Spinraza, Qalsody, salanersen and diranersen all came from that alliance) and in-house biologics manufacturing. Royalty income from Ocrevus and cash flow from mature drugs, $2.1 billion of free cash flow in 2025, fund acquisitions such as Reata and Apellis with cash and debt rather than new shares.
- Who are Biogen's competitors?
- Biogen's main competitors covered here are Roche, Novartis, Eli Lilly and Sanofi.
- What is Biogen's market share?
- Biogen does not report market share. Its Q2 2026 revenue by franchise gives a sense of scale: legacy MS portfolio $767 million (including Tysabri at $451 million and Vumerity at $197 million), Spinraza $402 million, Skyclarys $168 million, Syfovre $162 million for the full quarter, Zurzuvae $71 million and Leqembi $184 million of global in-market sales.
Core Strength
Decades of MS and SMA work give Biogen relationships with neurologists and treatment centers, experience running long CNS trials and in-house biologics manufacturing in North Carolina and Switzerland.
Key Weakness
Legacy MS revenue was $767 million in Q2 2026. Tecfidera lost US exclusivity in 2020, Tysabri faces biosimilars, and total revenue is about $4.5 billion below its 2019 peak.
Market Position & Competitive Landscape
In multiple sclerosis Biogen competes with Roche (Ocrevus, on which Biogen also earns royalties), Novartis (Kesimpta), Sanofi and Bristol Myers Squibb. In Alzheimer's disease its Leqembi partnership with Eisai competes with Eli Lilly's Kisunla. Roche's oral Evrysdi and Novartis's Zolgensma gene therapy compete with Spinraza in SMA, and Syfovre competes with Astellas's Izervay in geographic atrophy. Biogen has more than four decades of experience in neurology, including relationships with MS and SMA treatment centers and an alliance with Ionis that produced Spinraza and Qalsody. Its older products are shrinking: Tecfidera lost US exclusivity in 2020 and Tysabri faces biosimilars. Revenue peaked at $14.38 billion in 2019, fell to $9.84 billion by 2023 and has stabilised at $9.89 billion in 2025. Its Fit for Growth program, launched in 2023, targeted about $1 billion of gross savings. The Apellis purchase raised total debt to about $8.1 billion at the end of June 2026.
Key Competitors
| Competitor | Profile |
|---|---|
| Roche | View Profile → |
| Novartis | View Profile → |
| Eli Lilly | View Profile → |
| Sanofi | View Profile → |
Biogen Competitors, SWOT and Strategy FAQ
What is Biogen's strategy?
Under CEO Christopher Viehbacher, Biogen is cutting costs, growing newer drugs such as Leqembi, Skyclarys and Zurzuvae, and buying late-stage or marketed assets in rare disease, immunology and nephrology, such as Reata, HI-Bio and Apellis.
How does Leqembi compete with Eli Lilly's Kisunla?
Both are anti-amyloid antibodies for early Alzheimer's disease. Biogen and Eisai are leaning on convenience: Leqembi Iqlik, a weekly at-home subcutaneous injection, was approved for starting treatment in July 2026 and for maintenance after 18 months.
How does Spinraza hold up against Evrysdi and Zolgensma?
Spinraza still earned $402 million in Q2 2026, up 2%. Biogen is defending it with a high-dose regimen approved in March 2026 and developing salanersen, a once-a-year antisense successor now in Phase 3.
Why is Biogen moving beyond neurology?
Its legacy MS revenue is shrinking, so Biogen is adding growth in other specialist areas. Apellis brought eye and kidney drugs and a nephrology sales team, which Biogen plans to use for felzartamab, now in Phase 3.
Which partners matter most to Biogen?
Eisai (Leqembi), Ionis (Spinraza, Qalsody and antisense pipeline drugs), Genentech (anti-CD20 royalties), Supernus (Zurzuvae) and UCB (dapirolizumab pegol for lupus).
Who are Biogen's biggest competitors?
Roche, Novartis, Sanofi and Bristol Myers Squibb in multiple sclerosis; Eli Lilly in Alzheimer's disease; Roche and Novartis in spinal muscular atrophy; and Astellas in geographic atrophy.
What is Biogen's competitive advantage?
Their competitive moat is an absolute, multi-decade dedication to the most complex and failure-prone area of medicine: neurology. They are one of the only companies willing to repeatedly absorb the massive R&D costs required to tackle Alzheimer's disease.